ArticleJournal of the American Heart Association2026
Antimicrobial Use in Acute Myocardial Infarction-Related Cardiogenic Shock.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobial use (AMU) in acute myocardial infarction-related cardiogenic shock is common, but its prevalence, drivers, and outcomes are not well described.
methodsWe analyzed 1095 patients with acute myocardial infarction-related cardiogenic shock from the multicenter Northwell-Shock Registry (2016-2022). Patients undergoing coronary artery bypass surgery were excluded. AMU was defined as ≥24 hours of continuous therapy. Clinical features and outcomes were compared between AMU+ and AMU- groups.
resultsAntimicrobials were used in 55% of patients, and 70% of them were initiated within 48 hours of admission. Positivity was low in AMU+ cultures (12.6% blood, 20.4% urine), and resistant organisms were found in only 9.5% of positive blood cultures. In 70% of patients, AMU was prolonged despite negative cultures. Broad-spectrum agents were used in 84.9%. Anti-methicillin-resistant
conclusionsMore than half of patients with acute myocardial infarction-related cardiogenic shock received antimicrobials. Most patients received broad-spectrum coverage despite low microbial culture yield and the rare isolation of resistant organisms. These findings highlight the need for targeted stewardship strategies to optimize AMU in acute myocardial infarction-related cardiogenic shock.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.